Condition: Recurrent Glioblastoma · Sponsor: The University of Texas Health Science Center at San Antonio
This is an open-label single arm study. All patients will receive the study drug. The aim of the study is to compare overall survival (OS) of patients with recurrent brain tumor, known as Glioblastoma (GBM) having high levels of a protein, Trophoblast cell surface antigen 2 (Trop-2), expression on treatment with Sacituzumab Govitecan (SG) versus lomustine only which has been used in the past.
This description comes directly from the study's public registry record.
Epp Goodwin · 210-450-1000 · goodwine@uthscsa.edu
Always discuss trial participation with your own doctor first.
| Cleveland Clinic Taussig Cancer Center | Cleveland, Ohio, United States | Recruiting |
| Texas Oncology Austin | Austin, Texas, United States | Recruiting |
| University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center | San Antonio, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04559230